Li Zhuo, Li Zi-Jian, Xi Ya-Ming
Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.
Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):266-70. doi: 10.7534/j.issn.1009-2137.2016.01.051.
The incidence of HBV infection in lymphoma patients is much higher than that in the general normal population. HBV reactivation caused by treatment is one of the common complications in considerable amount of lymphoma patients, which can induce fatal fulminating hepatitis in severe cases. The HBV reactivation in lymphoma patients is related to multiple factors, such as age, sex, HBV infectious state, HBV genotypes and gene mutations, and antitumor drugs. It's necessary to strengthen monitoring, prevention and treatment to HBV reactivation in the process of dealing with lymphoma. This review focuses on the epidemiological characteristics of lymphoma and HBV, as well as the risk factors, morbidity, pathogenesis, clinical feature, suggestion on prevention and treatment of HBV reactivation.
淋巴瘤患者中乙肝病毒（HBV）感染的发生率远高于普通正常人群。治疗引起的HBV再激活是相当一部分淋巴瘤患者常见的并发症之一，严重时可诱发致命的暴发性肝炎。淋巴瘤患者的HBV再激活与多种因素有关，如年龄、性别、HBV感染状态、HBV基因型和基因突变以及抗肿瘤药物等。在淋巴瘤治疗过程中，有必要加强对HBV再激活的监测、预防和治疗。本文综述聚焦于淋巴瘤和HBV的流行病学特征，以及HBV再激活的危险因素、发病率、发病机制、临床特征、预防和治疗建议。
